Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial (Q38801610)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 May 2017

Language	Label	Description	Also known as
English	Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial	scientific article published on 2 May 2017

Statements

scholarly article

1 reference

Europe PubMed Central

6 September 2017

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial (English)

1 reference

Europe PubMed Central

6 September 2017

phase III clinical trial

0 references

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Francesco Merli

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Biljana Mihaljević

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Santiago Mercadal

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Noppadol Siritanaratkul

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Philippe Solal-Céligny

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Axel Boehnke

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Claude Berge

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Magali Genevray

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Artem Zharkov

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Mark Dixon

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Michael Brewster

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Martin Barrett

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

David MacDonald

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

2 May 2017

1 reference

Europe PubMed Central

6 September 2017

The Lancet. Haematology.

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

e272-e282

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Advances in the management of follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS2352-3026%2817%2930078-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2352-3026(17)30078-9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28476440%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38801610&oldid=1787768203"